Complement Component 3c and Tumor Necrosis Factor-α in Patients With Human Papillomavirus-Induced Cutaneous Warts

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04399577

Enrollment

Registered

2020-05-22

Start date

2017-07-01

Completion date

2019-09-03

Last updated

2020-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Warts

Brief summary

The investigators explore the role of the complement pathway and T helper 1 immune response in clinical response to Candida immunotherapy via complement component and tumor necrosis factor, respectively.

Detailed description

39 patients are enrolled in the study They suffer from chronic recurrent cutaneous warts Patients receive Candida antigen immunotherapy vial intra-lesional injection every 2 weeks till complete resolution or the maximum of 5 sessions Blood samples are withdrawn before and after intervention C3, C4, MBL, C3C and TNF alpha serum levels are measured

Interventions

BIOLOGICALCandida antigen

Patient receive candida antigen immunotherapy and blood samples will be withdrawn before and after intervention

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

9 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Chronic multiple cutaneous

Exclusion criteria

* Hypersensitivity to Candida antigen * Fever * Immunosuppressive disorders * Previous wart therapy in the last month

Design outcomes

Primary

Measure	Time frame	Description
Resolution of warts	12 weeks	100% clearance of warts

Secondary

Measure	Time frame	Description
Recurrence	6 months	Reappearance of warts

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026